– Leading cause of long-term disability
~$240B annual US cost in 2030
BB-031 has demonstrated superiority to TPA across multiple murine and canine preclinical models while BB-025 expands the clinical utility allowing for hemostatic mod.
Improved risk-benefit profile over SOC allows:
vWF drives both clot formation but also pathological expansion.
Our recently closed Seed Financing supports development of BB-031 through Phase 1B, in parallel with the NIH funded BB-025’s IND enabling program.